JSPR:NASDAQJasper Therapeutics, Inc. Analysis

Jasper Therapeutics is trading at $0.80, well below its 20‑day SMA of 0.996 and the 50‑day SMA of 1.208, confirming a bearish price trend. The RSI of 33 suggests the stock is approaching oversold territory, yet the MACD remains bearish with a negative histogram, reinforcing downside momentum. Volatility is extreme at 93% over the past 30 days and beta sits above 1.6, indicating the share moves sharply with the market. Fundamentals are weak: the company reports zero revenue, negative EBITDA of $‑80.5 M, and a trailing EPS of $‑3.95, while cash reserves are only $28.7 M against ongoing cash burn. No dividend is paid, and the price‑to‑book ratio of 5.42 is high for a cash‑negative biotech. Despite these challenges, analysts have a “buy” consensus with a mean price target of $7.70, driven by the upcoming clinical data for briquilimab and a proposed public offering that could shore up liquidity.
The combination of a deep discount to target, a potential capital raise, and the high upside implied by the upside/downside metric (>850%) creates a speculative play, but the high volatility, negative cash flows, and regulatory uncertainty in the biotech sector keep the risk profile elevated. Investors should weigh the possibility of a near‑term price bounce from news catalysts against the long‑term need for successful trial outcomes and additional financing.